Lamotrigine

Lamotrigine is a small-molecule medication of the phenyltriazine class, first developed by the Wellcome Foundation and later marketed under the brand name Lamictal along with many generics ^[3]. It is classed both as an antiepileptic drug and as a mood stabilizer, and it appears on the World Health Organization's list of essential medicines ^[3].

In the treatment of epilepsy, lamotrigine is used for a broad range of seizure types, including focal seizures and several kinds of generalized seizures, and it is one of a limited number of therapies approved for Lennox-Gastaut syndrome, a severe childhood epilepsy ^[1][3]. In psychiatry it is approved for the maintenance phase of bipolar I disorder, where its main value lies in delaying and preventing the return of mood episodes, especially depression; it is not, however, an effective treatment for acute mania and has only limited effect on an episode of acute depression already under way ^[2][3].

The drug is taken by mouth and is well absorbed, and it is cleared largely by the liver through a process called glucuronidation, which means its levels can be affected by other medicines that speed up or slow that pathway ^[3]. Its most important safety concern is the risk of serious skin reactions, including Stevens-Johnson syndrome; because this risk is greatest early in treatment and is linked to starting too high or increasing the amount too quickly, lamotrigine is introduced slowly ^[3]. More common and less serious effects include headache, dizziness, nausea, sleepiness, and unsteadiness ^[3]. Reviews of its use in bipolar disorder emphasize that, when it is titrated gradually, serious rash is uncommon ^[2][3].

Lamotrigine is a prescription medicine whose most important risk is skin rash, which is usually mild but can rarely progress to life threatening reactions such as Stevens Johnson syndrome or toxic epidermal necrolysis; the risk is higher with rapid dose increases or when combined with valproate. Other effects include dizziness, headache, double vision and insomnia, and rare serious reactions like DRESS and aseptic meningitis. Any new rash should be evaluated promptly, and the dose is always titrated slowly.

Oral hormonal contraceptives increase lamotrigine metabolism and significantly reduce its serum levels through induction of glucuronidation ^{[6] [7]}. Studies of women with epilepsy show that lamotrigine dose-corrected concentrations decrease 36 to 70 percent when using combined oral contraceptives, vaginal contraceptive rings, or transdermal patches containing estrogen ^[6]. Estrogen accelerates lamotrigine clearance; this is a pharmacokinetic interaction where the contraceptive increases the rate the body eliminates lamotrigine.

The effect depends on comedication; when lamotrigine is combined with valproate, oral contraceptives have no significant effect on either drug's clearance ^[7]. Women on lamotrigine monotherapy or lamotrigine plus carbamazepine experience the greatest lamotrigine level reductions. What is not well studied; the interaction with non-hormonal contraceptive methods, with progestin-only pills at various doses, or with newer long-acting reversible contraceptives beyond the commonly reported estrogen-containing methods.

Checking a whole stack? Run it through interactions + stacks.

Lamotrigine was developed by the pharmaceutical company Burroughs Wellcome in the United Kingdom during the 1980s, emerging from a research program that sought anticonvulsants among antifolate compounds; ironically, its antiseizure activity proved to rest on sodium channel blockade rather than folate antagonism. It received its first approvals for epilepsy in the early 1990s, reaching the United Kingdom in 1991 and the United States in 1994 under the brand name Lamictal.

Clinicians soon observed mood benefits in patients treated for seizures, prompting formal study in psychiatry. In 2003 the US Food and Drug Administration approved it for the long-term maintenance of bipolar I disorder, where it became distinctive for its ability to help prevent depressive episodes. It is now widely used across neurology and psychiatry and is included on the World Health Organization's List of Essential Medicines.

Lamotrigine has earned a strong and enduring reputation as a versatile, generally well tolerated medicine that spans epilepsy and mood stabilization. In bipolar disorder it holds a particular niche for preventing the depressive pole of the illness, an area where many treatments fall short, and controlled trials support its maintenance benefit with a tolerability profile comparable to placebo and often more favorable than lithium over the long term. Patients frequently appreciate that it tends to be weight neutral and non-sedating relative to older agents. The one serious caveat is well known and manageable; a small risk of severe rash, including Stevens-Johnson syndrome, which is why doses must be titrated slowly. Handled with that careful ramp-up, lamotrigine is considered a reliable and evidence-backed option, reflected in its place on the WHO essential medicines list.